Biofrontera on the Move: Company Raises $16M, Reduces Ameluz Transfer Price
Biofrontera has entered into a securities purchase agreement with healthcare-focused institutional investors led by Rosalind Advisors. The Company raised financing of $8M with an additional $8M tied to milestones for aggregate proceeds of $16M gross priced at market per Nasdaq rules. The stock soared with the announcement, according to media reports. This private placement is […]
FDA Fast Tracks Certa Therapeutics’ FT011 for Systemic Sclerosis
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis. FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs. It targets a GPCR receptor, GPCR68, with an extensive body of data demonstrating promising efficacy […]
IFPA Releases New Psoriatic Care Roadmap and Action Playbook for Asia
IFPA has released the Psoriatic Care Roadmap and Action Playbook for Asia. The new resources are guides featuring advocacy demands and practical strategies that aim to elevate psoriatic care across the continent. The roadmap addresses four crucial themes that emerged from the IFPA Forum Asia 2023, held in Singapore: 1. Access to Care for People with Psoriatic Disease 2. Addressing and Managing Comorbidities […]
PBUTs Linked to Itching in Hemodialysis Patients
Several uremic toxins may cause itching in hemodialysis patients, new research suggests. Although its exact causes remain unclear, itching in hemodialysis patients has been associated with elevated levels of β2-microglobulin, calcium, phosphorus, or parathyroid hormone in the blood. Subsequently, improvements in hemodialysis therapy and pharmacological treatments have led to changes in the severity of itching and […]
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
Almirall S.A. has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases. NN-8828 has the potential to block the activation of the downstream signaling pathways […]
Nevisense Bests TEWL for Evaluating Skin Barrier Function
Scibase’s Nevisense’s electrical impedance spectroscopy (EIS) may be a better way to assess skin barrier function than the trans-epidermal water loss (TEWL) measurement technique, a new study shows. Specifically, EIS was less affected by daily activities than TEWL, according to research in the Annals of Dermatology. The study included healthy adults between 22 and 65 years of age and aimed to […]
Targeting TYRP1 With CAR T-cell Therapy May Help Treat Cutaneous and Rare Melanomas
A new chimeric antigen receptor (CAR) T-cell-based immunotherapy targeting TYRP1 may help treat patients with cutaneous and rare subtypes of melanoma, according to research out of the UCLA Health Jonsson Comprehensive Cancer Center. The new approach, as described in Nature Communications, uses an engineered CAR T-cell that is designed to recognize and attack cells with […]
COVID-19 Lockdowns Caused Major Delays in Melanoma Diagnoses, Costing Billions
Delays in diagnosing melanoma due to COVID-19 lockdown may have contributed to more than 100,000 years of life lost across Europe and over £6 billion mainly indirectly due to loss of productivity, according to new research in JAMA Network Open. For the study, a team of researchers from the UK, Switzerland, Germany, US, Italy, Australia and Hungary, looked at […]
Can HA-based Fillers Reverse Photoaging?
Judicious use of sunscreen remains the best way to prevent photoaging, but now new research suggests that cross-linked hyaluronic acid soft tissue fillers may reverse the dermal changes associated with photoaging. The study appears in Experimental Dermatology. Cross-linked hyaluronic acid injections can stimulates production of new type I collagen in the dermis. The filler does so […]
Breaking News: Japan First in the World to Approve Dupilumab for CSU
The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. Japan is the first country to approve dupilumab […]